UCB SA (UCBJF) reports 23% net sales growth to EUR4.1 billion, with BIMZELX doubling to EUR1.5 billion and upgraded full-year guidance reflecting robust operating leverage.

Investing.com - European shares inched up on Thursday, as a massive wave of solid corporate earnings led by an energetic profit beat from oil major Shell helped offset an ambiguous interest rate outlook from the Federal Reserve and fresh U.S. airstrikes in Iran.

Investors may be wondering if UCB's share price still reflects good value after a strong run, or if most of the opportunity is already priced in. UCB's share price closed at €246.30, with a 1 year return of 68.3% and a 3 year return of 195.3%. The 7 day and 30 day returns of a 4.8% decline and a 0.4% decline suggest some recent cooling after a longer period of strength. Recent headlines around UCB have focused on its position in the pharmaceuticals and biotech space, as investors reassess...

Conference data puts UCB’s neurology pipeline in focus UCB (ENXTBR:UCB) is in the spotlight after presenting 21 neurology abstracts at the American Academy of Neurology 2026 meeting, including new real world data on developmental and epileptic encephalopathies and generalized myasthenia gravis. See our latest analysis for UCB. Despite a 1-day share price return of 1.32% to €246.3 after the neurology data updates, UCB’s recent 7-day and 90-day share price returns of 4.79% and 4.31% declines...

UCB (UCBJY) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UCB SA (UCBJF) reports robust financial performance with significant sales growth and strategic initiatives, despite facing market challenges.

UCB (ENXTBR:UCB) shares have caught more attention lately thanks to a mix of solid recent performance and strong momentum over the past month. Investors are watching closely to see if this trend continues. See our latest analysis for UCB. UCB’s share price has been quietly building momentum, with a solid 1-year total shareholder return of 0.5% reflecting investor confidence in the company's fundamentals and future prospects. Recent movements suggest the market is warming up to UCB's growth...

Stocks to watch this morning include CoreWeave (CRWV), the NVIDIA (NVDA)-backed AI cloud scaler, which is rising after some big swings in recent weeks. In the pharmaceutical sector, AstraZeneca (AZN) gains as it announces plans to list in New York, while GSK (GSK) and UCB SA (UCB.BR) are up on appointing a new CEO and positive trial results, respectively. And it's a high-stakes moment for Tesla (TSLA), BYD (1211.HK) and other makers of electric vehicles, amid a global slowdown and as a $7,500 tax credit comes to an end in the US. For more live coverage of markets watch the full episode of Market Sunrise and head to Yahoo Finance.

If you are looking for stocks that are well positioned to maintain their recent uptrend, UCB (UCBJY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

If you have been following UCB (ENXTBR:UCB), the recent moves in its share price have probably caught your eye. After an extended period of subdued trading, investors are starting to wonder if something is brewing beneath the surface. While there has been no eye-catching announcement or material event in the headlines to explain the uptick, such shifts often happen quietly, sometimes signaling changing market sentiment or an underappreciated story coming to light. Looking at the numbers,...

UCB (UCBJY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).